Stockscreener 앱 받기
0.00
100.00%
-0.2075
전일 마감가:
$0.2075
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$4.26M
수익:
$31.56M
순이익/손실:
$-46.89M
주가수익비율:
0.00
EPS:
-3.0329
순현금흐름:
$-26.70M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$3.09
Casi Pharmaceuticals Inc Stock (CASI) Company Profile
Compare CASI vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CASI
Casi Pharmaceuticals Inc
|
0.00 | 4.26M | 31.56M | -46.89M | -26.70M | -3.0329 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.38 | 126.81B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
774.66 | 81.62B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.09 | 45.97B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.43 | 42.76B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
298.91 | 33.88B | 5.36B | 287.73M | 924.18M | 2.5229 |
Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-05-18 | 개시 | BTIG Research | Buy |
| 2021-04-26 | 개시 | Mizuho | Buy |
| 2020-10-23 | 개시 | Oppenheimer | Outperform |
| 2016-09-22 | 개시 | Maxim Group | Buy |
| 2015-10-29 | 재개 | H.C. Wainwright | Buy |
| 2015-06-23 | 개시 | H.C. Wainwright | Buy |
모두보기
Casi Pharmaceuticals Inc 주식(CASI)의 최신 뉴스
Short Squeeze: Can CASI Pharmaceuticals Inc deliver consistent EPS growth2025 Valuation Update & Daily Stock Momentum Reports - baoquankhu1.vn
CASI Pharmaceuticals Inc. (CASIF) Price To Cash Flow - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Total Liabilities - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Return On Equity (TTM) - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Total Long Term Debt (Quarterly) - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Enterprise Value - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Total Expenses (Quarterly) - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Book Value - Zacks Investment Research
CASI PHARMACEUTICALS INC (CASIF.US) Income Statements, Balance Sheet & Cashflow - Longbridge
CASI PHARMACEUTICALS INC (CASIF.US) Latest News & Headlines - Longbridge
CASI Pharmaceuticals, Inc.: Financial Data Forecasts Estimates and Expectations | CASIF | KYG1933S1012 - marketscreener.com
CASI Pharmaceuticals, Inc.: Target Price Consensus and Analysts Recommendations | CASIF | KYG1933S1012 - marketscreener.com
CASI Pharmaceuticals, Inc.: Revenue and Earnings Analysts Forecasts Revisions | CASIF | KYG1933S1012 - marketscreener.com
Casi Pharmaceuticals CEO David Cory to step down at end of March - Investing.com
CASI Pharmaceuticals CEO David Cory to Step Down; Executive Chairman Wei-Wu He Assumes Top Role - TipRanks
Leadership change at CASI Pharmaceuticals (NASDAQ: CASI) as CEO exits - Stock Titan
CASI Pharmaceuticals Inc. (CASIF) Gross Margin (TTM) - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Debt Equity Ratio (Quarterly) - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Price Book Value - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Cash From Operations (TTM) - Zacks Investment Research
CASIF (CASI Pharmaceuticals) PB Ratio : (As of Mar. 02, 2026) - GuruFocus
CASI Pharmaceuticals Inc. (CASIF) Return On Assets (TTM) - Zacks Investment Research
Net debt of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
CASI Pharmaceuticals Inc. (CASIF) Earnings Yield (TTM) - Zacks Investment Research
EBIT per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
EBITDA margin % of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
After tax other income/expense of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Long term debt to total equity ratio of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Operating expenses (excl. COGS) of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
CapEx per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Net current asset value per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Preferred dividends of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Enterprise value to EBITDA ratio of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Working capital per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Total debt of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Free cash flow per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Total debt per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
CASI Pharmaceuticals, Inc. Balance Sheet – OTC:CASIF - TradingView
Technical Analysis of CASI Pharmaceuticals, Inc. (OTC:CASIF) - TradingView
CASI Pharmaceuticals Inc. (CASIF) Revenue (Quarterly) Yoy Growth - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Total Expenses (TTM) - Zacks Investment Research
Diluted shares outstanding of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Gross profit of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
EBIT of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Dilution adjustment of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Non-controlling/minority interest of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Free cash flow of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
CASI Pharmaceuticals, Inc. Statistics – OTC:CASIF - TradingView
EBITDA of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Pretax income of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Casi Pharmaceuticals Inc (CASI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.57%
0.40%
자본화:
|
볼륨(24시간):